MCID: URN009
MIFTS: 48

Urinary System Disease

Categories: Cancer diseases, Cardiovascular diseases, Nephrological diseases

Aliases & Classifications for Urinary System Disease

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 15 17
Abnormality of the Urinary System 29 6
Congenital Malformation of the Urinary System 70
Non-Neoplastic Urinary System Disorder 70
Non-Neoplastic Urinary Tract Disease 12
Urinary Tract Diseases 54
Urinary Tract Disease 12
Urinary Tract Anomaly 54
Urologic Diseases 70

Classifications:



External Ids:

Disease Ontology 12 DOID:18
NCIt 50 C27599
UMLS 70 C0042075 C0158698 C1335051

Summaries for Urinary System Disease

Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as abnormality of the urinary system, is related to kidney disease and bladder disease, and has symptoms including dysuria, polyuria and urgency of micturition. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Levoleucovorin and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include kidney, smooth muscle and bone.

Wikipedia : 73 The urinary system, also known as the renal system or urinary tract, consists of the kidneys, ureters,... more...

Related Diseases for Urinary System Disease

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 341)
# Related Disease Score Top Affiliating Genes
1 kidney disease 32.4 UMOD SIX1 MIR21 MIR200A MIR199A1 MIR17
2 bladder disease 32.4 MIR30A MIR21 MIR200A MIR199A1 MIR193A MIR17
3 urethral syndrome 32.4 KRT20 KLK3 H2AC18 CCR6
4 ureteral disease 32.4 MIR199A1 MIR142 CCR6
5 cakut 32.1 UMOD SIX1 MIR144
6 acute cystitis 31.2 UMOD KLK3 H2AC18 CCR6
7 urinary tract obstruction 31.1 UMOD MIR199A1 MIR142 KLK3 CCR6 B2M
8 bladder cancer 30.9 MIR21 MIR200A MIR193A MIR17 MIR145 MIR144
9 vesicoureteral reflux 1 30.9 UMOD SIX1 B2M
10 mycobacterium tuberculosis 1 30.8 MIR21 MIR144 ICOSLG H2AC18 CCR6
11 endometriosis 30.8 MIR200A MIR199A1 MIR145 MIR142 MIR141 MIR126
12 acute kidney tubular necrosis 30.7 UMOD MIR142 B2M
13 sexual disorder 30.7 MIR141 KLK3 H2AC18
14 pyuria 30.6 KLK3 B2M
15 urethral stricture 30.5 MIR21 KLK3
16 hematuria, benign familial 11.0
17 urolithiasis 11.0
18 urinary tract infection 11.0
19 bacteriuria 11.0
20 lower urinary tract calculus 11.0
21 bone marrow cancer 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR142
22 leukocyte disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR144 MIR142
23 autoimmune disease of musculoskeletal system 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR142 MIR126
24 autonomic nervous system neoplasm 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR142
25 ovary epithelial cancer 10.7 MIR30A MIR21 MIR200A MIR199A1 MIR193A MIR17
26 malignant ovarian surface epithelial-stromal neoplasm 10.7 MIR30A MIR21 MIR200A MIR199A1 MIR193A MIR17
27 peripheral nervous system neoplasm 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR142
28 bile duct adenocarcinoma 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR144
29 overnutrition 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR144 MIR142
30 central nervous system disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR144
31 myeloma, multiple 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR145 MIR142
32 mature b-cell neoplasm 10.7 MIR199A1 MIR17 MIR142 MIR126 ICOSLG H2AC18
33 oral cavity cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
34 leukemia, chronic lymphocytic 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
35 connective tissue cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
36 disease by infectious agent 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR144 MIR142
37 bone inflammation disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR142 MIR126
38 autosomal genetic disease 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR144 MIR142
39 blood protein disease 10.7 MIR17 MIR126 ICOSLG H2AC18 CFHR2 CCR6
40 glucose metabolism disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR144 MIR142
41 central nervous system cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
42 hematologic cancer 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR145
43 intestinal benign neoplasm 10.7 MIR21 MIR199A1 MIR17 MIR145 MIR142 H2AC18
44 skin disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR142 MIR126
45 peripheral nervous system disease 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR144 MIR142
46 integumentary system disease 10.7 MIR30A MIR21 MIR199A1 MIR17 MIR142 MIR126
47 immune deficiency disease 10.7 MIR21 MIR199A1 MIR17 MIR142 MIR126 ICOSLG
48 contractures, pterygia, and spondylocarpotarsal fusion syndrome 1a 10.7 MIR21 MIR199A1 MIR17 MIR142 MIR126 ICOSLG
49 nasopharyngeal disease 10.7 MIR30A MIR21 MIR199A1 MIR193A MIR17 MIR144
50 extrinsic cardiomyopathy 10.7 MIR21 MIR199A1 MIR142 ICOSLG H2AC18 CCR6

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease

Symptoms & Phenotypes for Urinary System Disease

UMLS symptoms related to Urinary System Disease:


dysuria; polyuria; urgency of micturition; other and unspecified genitourinary symptoms; renal colic; pain in urethra; uti symptoms; urethral burning on micturition; loin pain; ureteral pain; flank tenderness; difficulty passing urine; urinary tenesmus; burning urination; bladder discomfort; renal pain; urologic problem

Drugs & Therapeutics for Urinary System Disease

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 165)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Investigational Phase 4 68538-85-2 149436
2
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3
Bupivacaine Approved, Investigational Phase 4 38396-39-3, 2180-92-9 2474
4
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
5
Uric acid Investigational Phase 4 69-93-2 1175
6 Protective Agents Phase 4
7 Micronutrients Phase 4
8 Trace Elements Phase 4
9 Nutrients Phase 4
10 Vitamin B Complex Phase 4
11 Antioxidants Phase 4
12 Folate Phase 4
13 Vitamins Phase 4
14 Vitamin B9 Phase 4
15 Hematinics Phase 4
16 Neuromuscular Nondepolarizing Agents Phase 4
17 Neuromuscular Blocking Agents Phase 4
18 Anticonvulsants Phase 4
19 Bromides Phase 4
20 Anesthetics Phase 4
21 Anesthetics, Local Phase 4
22 Narcotics Phase 4
23 Analgesics, Opioid Phase 4
24
Tamsulosin Approved, Investigational Phase 3 106133-20-4 129211
25
Mirabegron Approved Phase 3 223673-61-8 9865528
26
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
27
tannic acid Approved Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
29
Ofloxacin Approved Phase 3 82419-36-1 4583
30
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
31
Lomefloxacin Approved, Investigational Phase 3 98079-51-7 3948
32
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
33
Pregabalin Approved, Investigational Phase 3 148553-50-8 5486971
34 Adrenergic Agonists Phase 3
35 Adrenergic beta-3 Receptor Agonists Phase 3
36 Cholinergic Antagonists Phase 3
37 Solifenacin succinate Phase 3 242478-38-2
38 Cholinergic Agents Phase 3
39 Adrenergic beta-Agonists Phase 3
40 Muscarinic Antagonists Phase 3
41 Adrenergic Agents Phase 3
42 Neurotransmitter Agents Phase 3
43 Analgesics Phase 3
44 Anti-Bacterial Agents Phase 3
45 Anti-Infective Agents Phase 3
46 Hormones Phase 3
47 Calcium, Dietary Phase 3
48 Parasympatholytics Phase 3
49 Cytochrome P-450 Enzyme Inhibitors Phase 3
50 Psychotropic Drugs Phase 3

Interventional clinical trials:

(show top 50) (show all 107)
# Name Status NCT ID Phase Drugs
1 Periprocedural Administration of Folic Acid for Prevention of Contrast Induced Nephropathy in Patients Undergoing Coronary CTA/Angiography/Angioplasty Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Efficacy of the Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures Recruiting NCT02805504 Phase 4 Exparel;Marcaine
3 Does Depth of Neuromuscular Blockade (NMB) Affect Surgical Conditions and Postoperative Pain in Obese Patients Undergoing Robotic Surgery Recruiting NCT03591289 Phase 4 NMB with rocuronium bromide
4 A Randomized Trial Evaluating Use of Long-Acting Liposomal Bupivacaine (Exparel®) in Reducing Narcotic Pain Requirements in Pediatric Patients Undergoing Minor Urologic Procedures Not yet recruiting NCT04826484 Phase 4 Exparel 133 MG Per 10 ML Injection;Bupivacaine Hydrochloride
5 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Male Patients With Lower Urinary Tract Syndrome Completed NCT00239317 Phase 3 Tamusulosin
6 Tamsulosin Phase III Clinical Trial -Double-Blind, Placebo Controlled Study in Female Patients With Lower Urinary Tract Syndrome Completed NCT00239265 Phase 3 Tamuslosin
7 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
8 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
9 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
10 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
11 A Multicenter, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Lomefloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258102 Phase 3 Levofloxacin
12 A Multicenter, Double-Blind, Randomized Study To Compare The Safety And Efficacy Of Oral Levofloxacin With That Of Ciprofloxacin HCl In The Treatment Of Complicated Urinary Tract Infections In Adults Completed NCT00258089 Phase 3 Levofloxacin
13 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
14 Perioperative Pregabalin as Part of a Multimodal Treatment Plan for Pain After Ureteroscopy With Stent Placement: a Pilot Completed NCT03927781 Phase 3 Pregabalin 300mg
15 An Open-Label Roll-Over Study to Evaluate the Long-Term Safety and Efficacy of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Enrolling by invitation NCT04042402 Phase 3 DCR-PHXC
16 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
17 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
18 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
19 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
20 Muscle Cell Mediated Therapy for Stress Urinary Incontinence in Males Following Prostate Surgery: An Investigation of Cook MyoSite Autologous Muscle Derived Cells Completed NCT02291432 Phase 1, Phase 2
21 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
22 Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II. Recruiting NCT03562897 Phase 2
23 A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease Recruiting NCT04387448 Phase 2 GFB-887;Placebo
24 A Phase 2 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of DCR-PHXC Solution for Injection (Subcutaneous Use) in Patients With Primary Hyperoxaluria Active, not recruiting NCT03847909 Phase 2 DCR-PHXC;Sterile Normal Saline (0.9% NaCl)
25 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Active, not recruiting NCT03081858 Phase 1, Phase 2 TSD-001
26 Intravesical Antifibrinolytic for Patients With Hematuria and Clot Retention Not yet recruiting NCT04555343 Phase 1, Phase 2 Tranexamic acid
27 Albumin Normalization to Prevent Hypotension and Enhance Recovery From Severe Acute Kidney Injury Treated With Renal Replacement Therapy: A Proof-of-Concept Study Not yet recruiting NCT04705896 Phase 2
28 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
29 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
30 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
31 A First-In-Human, Phase 1, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GFB-887, a TRPC5 Channel Inhibitor, in Healthy Subjects Completed NCT03970122 Phase 1 GFB-887;Placebo
32 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fasted State in Healthy Adult Male Subjects Completed NCT02052713 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
33 A Single-Dose, Randomised, Open-Label, Two-Period Crossover Study to Determine the Bioequivalence of the Second Generation Dutasteride and Tamsulosin HCl Combination Capsule in the Fed State in Healthy Adult Male Subjects Completed NCT02058576 Phase 1 Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg;Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule
34 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01231997 Phase 1 Udenafil
35 Clinical Study to Investigate the Safety and Pharmacokinetics of Udenafil Tablet in Renal Impaired Male Patients Completed NCT01232010 Phase 1 Mirodenafil
36 Pilot Study of Mycophenolate Mofetil in Congenital Uropathies Completed NCT00193635 Phase 1 mycophenolate mofetil
37 Perioperative Testosterone Replacement Therapy Improves Outcomes: A Pilot Safety and Feasibility Study Recruiting NCT04731376 Phase 1 Testosterone Cypionate
38 Phase 1 Pilot Study of Bioengineered Penile Tissue Constructs in Subjects With Irreversibly Damaged Penile Corpora Not yet recruiting NCT03463239 Phase 1
39 A Phase 1 Pilot Safety and Feasibility Study of Autologous Engineered Urethral Not yet recruiting NCT03258658 Phase 1
40 Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Administration for Orthopedic, Neurologic, Urologic, Autoimmune, Renal, Cardiac and Pulmonary Conditions Not yet recruiting NCT03899298 Phase 1
41 A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer Terminated NCT02543645 Phase 1 Combination of Varlilumab and Atezolizumab
42 A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02386111 Phase 1 Combination of varlilumab and sunitinib
43 Pharmacology and Physiology of the Lower Urinary Tract Unknown status NCT00662064
44 The Alternating Bidirectional Versus The Standard Approach During Shock Wave Lithotripsy For Renal And Upper Lumbar Ureteric Stones. A Randomized Clinical Trial Unknown status NCT03243682
45 A Randomized Controlled Trial of Renal Hypothermia During Partial Nephrectomy Unknown status NCT01529658
46 Remote Ischemic Conditioning (RIC) to Decrease Post-Operative Complications After Major Abdominal Surgery - A Phase IIa Trial Unknown status NCT03234543
47 Bladder Morphology Using 2 Different Catheter Designs Foley Catheter vs. Cystosure Urinary Access System Unknown status NCT03108079
48 Brain Effects of Sacral Neuromodulation in Patients With Refractory Lower Urinary Tract Dysfunction Completed NCT00610064
49 A Prospective, Multi-center, Single-arm Study to Evaluate the Safety and Efficacy of LithoVue Ureteroscope System in Chinese Patients With Urinary Disease(LithoVue China Study) Completed NCT03676972
50 Patient-driven Compression in Urography Completed NCT02622269

Search NIH Clinical Center for Urinary System Disease

Genetic Tests for Urinary System Disease

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 29

Anatomical Context for Urinary System Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary System Disease:

19
Kidney

MalaCards organs/tissues related to Urinary System Disease:

40
Kidney, Smooth Muscle, Bone, Prostate, Liver, Lung, Skin

Publications for Urinary System Disease

Articles related to Urinary System Disease:

(show all 50)
# Title Authors PMID Year
1
Unilateral T-shaped incomplete duplex nephrectomy in an adolescent under laparoscopy: A case report. 61
33761700 2021
2
Metabolomics analysis of serum in pediatric nephrotic syndrome based on targeted and non-targeted platforms. 61
33788045 2021
3
Dysbiosis of urine microbiota in obstructive urinary retention patients revealed by next-generation sequencing. 61
33407528 2021
4
[Visual analysis of knowledge map of network Meta-analysis in traditional Chinese medicine based on CiteSpace]. 61
33164381 2020
5
Acupuncture combined with tamsulosin hydrochloride sustained-release capsule in the treatment of chronic prostatitis/chronic pelvic pain syndrome: A study protocol for a randomized controlled trial. 61
32195959 2020
6
Forsythiaside A alleviates renal damage in adriamycin-induced nephropathy. 61
31585901 2020
7
Guidelines of the Italian Society of Videosurgery in Infancy for the minimally invasive treatment of the ureteropelvic-junction obstruction. 61
32323520 2019
8
Traditional Chinese medicine on treating chronic prostatitis/chronic pelvic pain syndrome: A systematic review and meta-analysis. 61
31261537 2019
9
Effectiveness comparisons of acupuncture for chronic prostatitis/chronic pelvic pain syndrome: A Bayesian network meta-analysis protocol. 61
31027066 2019
10
New method to preserve the original proportion and integrity of urinary cell-free DNA. 61
30175467 2019
11
Pilot study on serum C-reactive protein in pet rabbits: clinical usefulness. 61
31565226 2019
12
Risk factors and medical costs for healthcare-associated carbapenem-resistant Escherichia coli infection among hospitalized patients in a Chinese teaching hospital. 61
28095785 2017
13
Stem Cell Therapy for Treatment of Stress Urinary Incontinence: The Current Status and Challenges. 61
26880983 2016
14
Novel Transparent Urinary Tract Simulator Improves Teaching of Urological Operation Skills at a Single Institution. 61
25720440 2015
15
[Recent progress of small intestinal submucosa in application research of tissue repair and reconstruction]. 61
24279031 2013
16
[Retrograde nephrolithotripsy in patient with an abnormality of the urinary system]. 61
24159774 2013
17
Mortality causes in cancer patients with type 2 diabetes mellitus. 61
21960185 2012
18
Correlates of quality of life in China rural-urban female migrate workers. 61
21695594 2012
19
Synthesis and Vasorelaxant Effect of 9-aryl-1,8-acridinediones asPotassium Channel Openers in Isolated Rat Aorta. 61
24250444 2012
20
What do prostate cancer patients die of? 61
21257717 2011
21
[Epidemiological study of women adults with mixed urinary incontinence in China]. 61
20973221 2010
22
Epidemiology of mixed urinary incontinence in China. 61
20022321 2010
23
SIX1 acts synergistically with TBX18 in mediating ureteral smooth muscle formation. 54
20110314 2010
24
Thyroidization in renal allografts. 54
19594588 2009
25
Quantitative detection of cytokeratin 20 mRNA in urine samples as diagnostic tools for bladder cancer by real-time PCR. 54
19300416 2009
26
Prevalence of mutations in renal developmental genes in children with renal hypodysplasia: results of the ESCAPE study. 54
16971658 2006
27
[The results of surgery on HIV carriers with urinary system disease]. 61
16281512 2005
28
[Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis]. 54
16321281 2005
29
Practice of opportunistic prostate-specific antigen screening in Italy: data from the Health Search database. 54
15452450 2004
30
Health effects in community residents near a uranium plant at Fernald, Ohio, USA. 61
12921382 2003
31
[Implications of beta 2-microglobulin in the detection of associated urinary tract diseases in patients with infiltrative pulmonary tuberculosis]. 54
12577571 2002
32
[Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract]. 61
12508552 2002
33
Inflamed urachal cyst containing calculi in an adult. 61
11981938 2002
34
Urine detection of survivin and diagnosis of bladder cancer. 54
11176843 2001
35
Urinary cytokeratin 20 as a marker for transitional cell carcinoma. 54
10765100 2000
36
Serum beta 2-microglobulin in fetuses with urinary tract anomalies. 54
9024089 1997
37
[Value of serum PSA and PAP measurement with newly developed latex turbidimetric immunoassay]. 54
7544063 1995
38
Urinary levels of the renal tubular enzyme N-acetyl-beta-D-glucosaminidase in unilateral obstructive uropathy. 54
8283554 1994
39
Use of serum gamma-enolase and aldolase A in combination as markers for renal cell carcinoma. 54
8486529 1993
40
Elevated levels of serum aldolase A in patients with renal cell carcinoma. 54
1509638 1992
41
Amniotic fluid N-acetyl-beta-D-glucosaminidase activity and renal abnormalities. 54
1750765 1991
42
[Prostatic specific antigen (PSA). Interpretation of results as a function of the assay method]. 54
1726942 1991
43
[Urinary Tamm-Horsfall protein coating of free cells and its clinical diagnostic significance]. 54
1864173 1991
44
[Prostate-specific antigen. Interpretation of the results in relation to the sampling method]. 54
1720942 1991
45
[Detection of beta-lactamase-producing strains isolated from urinary tract and their drug susceptibility]. 54
2399858 1990
46
Prostate-specific antigen in prostatic carcinoma. 54
1693455 1990
47
Comparison of urinary protein concentration and protein/creatinine ratio vs routine microscopy in urinalysis of dogs: 500 cases (1987-1988). 61
2793583 1989
48
Urinary tract endometriosis. 61
2921125 1989
49
Ultrasonography in the radiologic evaluation of children with urinary tract infection. 61
3523415 1986
50
The perplexing problem of prostatitis. 61
1181582 1975

Variations for Urinary System Disease

ClinVar genetic disease variations for Urinary System Disease:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 CHD1L NM_004284.6(CHD1L):c.234C>T (p.Thr78=) SNV Uncertain significance 625178 rs1311096135 GRCh37: 1:146724384-146724384
GRCh38: 1:147252729-147252729

Expression for Urinary System Disease

Search GEO for disease gene expression data for Urinary System Disease.

Pathways for Urinary System Disease

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIR30A MIR21 MIR200A MIR199A1 MIR17 MIR145
2 10.07 MIR199A1 MIR145

GO Terms for Urinary System Disease

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.36 UMOD MIR30A MIR21 MIR199A1 MIR17 MIR144
2 extracellular vesicle GO:1903561 9.35 MIR30A MIR21 MIR193A MIR17 MIR126

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 9.67 MIR21 MIR144 MIR126
2 positive regulation of angiogenesis GO:0045766 9.67 MIR30A MIR21 MIR199A1 MIR126
3 positive regulation of blood vessel endothelial cell migration GO:0043536 9.58 MIR30A MIR200A MIR126
4 negative regulation of inflammatory response GO:0050728 9.56 MIR145 MIR142 MIR141 MIR126
5 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.51 MIR199A1 MIR17
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.5 MIR21 MIR199A1 MIR145
7 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.48 MIR199A1 MIR17
8 positive regulation of metalloendopeptidase activity GO:1904685 9.46 MIR21 MIR17
9 negative regulation of angiogenesis GO:0016525 9.46 MIR21 MIR193A MIR145 KLK3
10 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.43 MIR21 MIR17
11 gene silencing by miRNA GO:0035195 9.36 MIR30A MIR21 MIR200A MIR199A1 MIR193A MIR17
12 miRNA mediated inhibition of translation GO:0035278 9.26 MIR21 MIR17 MIR145 MIR144

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.61 MIR30A MIR21 MIR193A MIR17 MIR145 MIR144
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.36 MIR30A MIR21 MIR200A MIR199A1 MIR193A MIR17

Sources for Urinary System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....